In the post-Jack Abramoff era, when the term "lobbying" is bandied about, people are likely to think the worst. But in certain cases when special interests pursue their goals, it turns out to be the best move for everyone. While some will no doubt vociferously disagree, Merck's
The Associated Press reports that Merck has been shelling out cash to the group Women in Government, an organization of female state legislators across the country, in an effort to get Gardasil included as a mandatory vaccination in as many states as possible. HPV is linked to most cases of cervical cancer, so compulsory vaccination could be a major boon to women's health, in addition to boosting Merck's bottom line.
However, not everyone is enthusiastic about the idea. HPV is transmitted sexually, and some strains can cause genital warts. To inoculate against the virus, women must be vaccinated before they become sexually active, and the treatment can be given as early as age 11. Some conservatives have argued that by blocking a sexually transmitted disease, vaccination would encourage premarital sex, thereby undermining efforts to promote abstinence.
In the end, though, I think Merck will likely succeed in getting states to see its perspective. For one thing, most states will probably allow parents to opt out of vaccination. For another, it's not as if parents must discuss the sexual implications of vaccination with their 11-year-olds. And finally, many states now mandate childhood vaccination against hepatitis B, which also can be transmitted sexually.
For Merck, of course, getting states to mandate Gardasil's use doubtless would mean huge sales. The vaccine brought in $235 million in sales in 2006, despite having been on the market only since July.
Still, investors shouldn't necessarily bet everything on Gardasil. GlaxoSmithKline
For related content:
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.